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Summary
Objective: Increased levels of glutamate, the main excitatory neurotransmitter, are found in the synovial ﬂuid of osteoarthritis (OA) patients.
Our aim was to study glutamate signaling in chondrocytes, focusing on the composition, pharmacology, and functional role of N-methyl-D-as-
partate (NMDA) glutamate receptors.
Methods: We used the human chondrocyte cell line SW1353 and, in parallel, primary rat articular chondrocytes. Glutamate release and uptake
were measured by ﬂuorimetric and radiometric methods, respectively. Gene expression was analyzed by quantitative polymerase chain
reaction. NMDA receptor pharmacology was studied in binding experiments with [3H]MK-801, a speciﬁc NMDA receptor antagonist. RNA
interference was used to knock-down the expression of NR1, a subunit of NMDA receptors.
Results: Glutamate release, sodium- and calcium-dependent glutamate uptake, and the expression of a glutamate transporter were observed
in chondrocytes. NR2D was the most abundant NMDA receptor subunit in these cells. Consistent with this observation, the binding afﬁnity of
[3H]MK-801 was much lower in chondrocytes than in rat brain membranes (mean Kd values of 700 and 2.6 nM, respectively). NR1 knock-
down, as well as NMDA receptor blockade with MK-801, reduced chondrocyte proliferation. Interleukin (IL)-1b signiﬁcantly altered glutamate
release and uptake (about 90% increase and 50% decrease, respectively, in SW1353 cells). Moreover, IL-1b induced the gene expression of
cytokines and enzymes involved in cartilage degradation, and MK-801 signiﬁcantly inhibited this response.
Conclusions: Our ﬁndings suggest that chondrocytes express a self-sufﬁcient machinery for glutamate signaling, including a peripheral NMDA
receptor with unique properties. This receptor may have a role in the inﬂammatory process associated with cartilage degradation, thus emerg-
ing as a potential pharmacological target in OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Glutamate is the main excitatory neurotransmitter in the
central nervous system (CNS). However, the discovery
that glutamate signaling is functional in peripheral tissues
(neuronal and non-neuronal) indicates that it may also act
as an autocrine and/or paracrine mediator to inﬂuence
many cellular activities1e3. Some studies in the late nineties
have suggested that glutamate is one of the endogenous
factors used for intercellular communications in bone4,5.
Both ionotropic and metabotropic glutamate receptors are
expressed in bone cells, and the activity of N-methyl-D-as-
partate (NMDA) receptors, which belong to the ionotropic
glutamate receptor family, is modulated in vitro by speciﬁc
antagonists such as MK-8016e8.
Various components of the glutamate system have been
recently detected in cartilage cells. For instance, rat costal
chondrocytes express mRNA for NMDA and non-NMDA re-
ceptors9,10. In addition, these cells express different excit-
atory amino acid transporters (EAATs), including the glial*Address correspondence and reprint requests to: Dr Tiziana
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1076subtypes glutamate transporter-1 (GLT-1) and glutamate/
aspartate transporter (GLAST)11. We owe to Salter and
his group the ﬁrst demonstration that the NMDA receptor
is present in human articular cartilage in vivo, together
with the hypothesis that it may be involved in biomechanical
responses12. In parallel, other authors have reported on in-
creased glutamate and cytokine levels in the synovial ﬂuid
of patients with active arthropathies13,14, consistent with
the recent ﬁnding that NMDA receptors on human synovio-
cytes may contribute to joint inﬂammation and destruction in
rheumatoid arthritis (RA)15. However, little attention has
been paid to the possible involvement of chondrocytes in
the inﬂammatory response mediated by glutamate at the
joint level. The contribution of chondrocytes to this process
might be relevant to osteoarthritis (OA), a disease in which
inﬂammation plays a role regardless of its classiﬁcation as
a non-inﬂammatory arthropathy16.
Thus, an experimental study was undertaken to investi-
gate the role of glutamate signaling in cartilage physiology
and pathology. We used the human chondrosarcoma cell
line SW1353, a well-established chondrocyte model17,18,
and, in parallel, primary cultures of rat articular chondro-
cytes. Here we describe a self-sufﬁcient machinery for glu-
tamate signaling, the composition and pharmacology of the
NMDA receptor expressed in chondrocytes, and the poten-
tial role of this receptor under physiological and pathological
conditions.
1077Osteoarthritis and Cartilage Vol. 17, No. 8Materials and methodsMATERIALSLeibovitz’s MediumþGlutaMAX I, Dulbecco’s modiﬁed Eagle Medium
(DMEM)þGlutaMAX I, Dulbecco’s phosphate-buffered saline (PBS), Hanks’
balanced salt solution (HBSS), Trypsin/EDTA, and FM1-43 were purchased
from Invitrogen (Carlsbad, CA). Hyaluronidase, trypsin, collagenase, recombi-
nant human interleukin (IL)-1b (100.000 U/ml, 2 mg/ml), and FuGENE 6
Transfection Reagent were from Roche (Indianapolis, IN). MK-801 and DL-
threo-b-benzyloxyaspartate (TBOA) were from Tocris Cookson (Avonmouth,
UK). EDTA, NADPþ and glutamate dehydrogenase (GDH) were obtained
from Sigma (St. Louis, MO). [3H]MK-801 (speciﬁc activity 17e22 Ci/mmol),
[3H]glutamate (speciﬁc activity 52 Ci/mmol), and UltimaGold-MV were pur-
chased from PerkinElmer Life and Analytical Sciences (Wellesley, MA).CELL CULTURESSW1353 cells (human chondrosarcoma cell line from ATCC, Promochem,
UK) were grown adherent at 37C, without CO2, in Leibovitz’s medium sup-
plemented with 10% fetal bovine serum (FBS) and gentamicin (50 mg/ml).
SW1353 cells were plated at a density of 3 104 cells/cm2. For expression
analysis, conﬂuent cells were synchronized by incubation in Leibovitz’s me-
dium for 16 h, in the presence of 0.4% FBS. All experiments were performed
using cells at passages 5 through 18.
Rat articular chondrocytes were obtained from young adult Sprague Daw-
ley male rats (7 weeks; Charles River, Calco, Italy). All studies involving ani-
mals were carried out in accordance with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the USNational Institutes
of Health. Articular cartilage from shoulders, femoral heads, and knees was
prepared according to Berenbaum and colleagues19. The cell suspension
was then diluted to 104 cells/ml and seeded into 12-well culture plates (1 ml/
well) in DMEM supplemented with 10% FBS and gentamicin (50 mg/ml). Cells
reached conﬂuence in 12e14 days. For expression analysis, conﬂuent cells
were synchronized for 16 h in DMEM supplemented with 0.4% FBS.
To study the effect of NMDA receptor blockade on gene expression, cells
were pre-treated with MK-801 for 1 h before stimulation with IL-1b (2 ng/ml)
for 6 h. The drug concentrations used for gene expression experiments were
selected after toxicity analysis (viability assay using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide [MTT]).GLUTAMATE DETERMINATIONLevels of glutamate were determined by ﬂuorimetric assay, according to
Genever and Skerry20. Fluorescence was monitored for 30 min, at 5 min inter-
vals, using excitation and emission wavelengths of 355 nm and 460 nm,
respectively (VICTOR ﬂuorescence reader; PerkinElmer, Wellesley, MA). To
quantify glutamate levels, a standard curve was constructed for each assay
with known concentrations of glutamate (0.8e25 mM). Intracellular concentra-
tion of glutamatewas assessed after cell permeabilizationwith 1%TritonX-100.GLUTAMATE UPTAKECells were washed with N-(2-Hydroxyethyl)piperazine-N 0-(2-ethanesul-
fonic acid) (HEPES) Krebs-Ringer (HKR) (125 mM NaCl, 3.5 mM KCl,
1.5 mM CaCl2, 1.2 mM MgSO4, 1.25 mM KH2PO4, 25 mM NaHCO3,
10 mM HEPES, and 10 mM D-glucose, pH 7.4) buffer. Cells were then incu-
bated at 37C for 20 min in HKR buffer containing 25 nM [3H]glutamate. The
reaction was terminated by removing the buffer and rinsing with ice-cold
HKR buffer; washed cells were then solubilized in 0.1 M NaOH. For liquid
scintillation spectrometry, 8 ml of UltimaGold-MV were used. Protein concen-
tration was determined using a Bio-Rad Protein Assay Kit (Hercules, CA),
and results were normalized to protein content. To further characterize gluta-
mate uptake into chondrocytes, tests were performed in HKR buffer without
Ca2þ or Naþ, with increasing concentrations of Ca2þ, with EDTA, and in HKR
buffer containing TBOA.VESICLE RECYCLINGVesicle recycling was investigated by using the membrane probe FM1-43,
a water-soluble dye, non-toxic to cells and non-ﬂuorescent in aqueous me-
dium. This method is generally used for identifying actively ﬁring neurons
and was previously used for the labeling of recycling vesicles in osteoblastic
cells20. In brief, after 5 min pre-incubation in recycling buffer (HBSS supple-
mented with CaCl2, 1 mM), cells were exposed to 10 mM FM1-43 for different
time periods (up to 20 min). At the end of incubation, cells were washed and
ﬁxed in 4% paraformaldehyde for 30 min, then mounted and viewed with
a ﬂuorescence microscope (Axioskope-Zeiss, Germany). For destaining ex-
periments, cells were exposed to the dye for 20 min, then washed in FM1-43-
free HBSS for 30 min before ﬁxation.TOTAL RNA PURIFICATIONTotal RNA was puriﬁed using ABI PrismTM 6100 Nucleic Acid PrepSta-
tion, an RNA isolation platform from Applied Biosystems (Foster City, CA).REVERSE TRANSCRIPTION (RT)Total RNA was retrotranscribed with the High-Capacity cDNA Archive Kit
(Applied Biosystems) by adding 50 ml of total RNA to 50 ml of reaction mix
(following the manufacturer’s protocol). The reaction (ﬁnal volume: 100 ml)
was carried out in a Bio-Rad (Hercules, CA) ‘‘iCycler’’.QUANTITATIVE POLYMERASE CHAIN REACTION
(PCR)dREAL-TIME PCR (RT-PCR)All primers and probes were purchased from Applied Biosystems as Taq-
Man Gene Expression Assays, with the exception of the primers and
probes for the endogenous controls glyceraldehyde-3-phosphate dehydro-
genase (GAPDH; human) and 18S (rat), which were purchased as PDARs
(Pre-Developed TaqMan Assay Reagents).
Identiﬁcation codes for the human primers and probes are as follows:
GLAST-1 (Hs00188193_m1), NR1 (Hs00246956_m1), NR2A (Hs00168"-
219_m1), NR2B (Hs00168230_m1), NR2C (Hs00168236_m1), NR2D
(Hs00181352_m1), postsynaptic density-95 (PSD-95; Hs00176354_m1), IL-
1b (Hs00174097_m1), IL-6 (Hs00174131_m1), cyclooxygenase-2 (COX-2;
Hs00153133_m1), matrix metalloproteinase-3 (MMP-3; Hs00233962_m1).
Identiﬁcation codes for the rat primers and probes are as follows: GLAST-
1 (Rn00570130_m1), NR1 (Rn00433800_m1), NR2A (Rn00561341_m1),
NR2B (Rn00561352_m1), NR2C (Rn00561364_m1), NR2D (Rn005756"-
38_m1), PSD-95 (Rn00571479_m1), IL-1b (Rn00580432_m1), IL-6
(Rn00561420_m1), COX-2 (Rn00568225_m1), MMP-3 (Rn00591740_m1).
The reaction was performed using the ABIPRISM 7000 Sequence Detec-
tion System, and each sample was analyzed in triplicate. Data were normal-
ized according to the ampliﬁed values of GAPDH/18S, with the aid of the
Relative Quantiﬁcation/RQ Software (Applied Biosystems).WESTERN BLOTCells were lysed with the M-PER Eukaryotic Protein extraction kit (Pierce,
Rockford, IL) in the presence of Halt Protease Inhibitor Cocktail kit (Pierce).
Protein extracts were electrophoresed on 8% sodium dodecyl sulfate-
polyacrylamide (SDS-polyacrylamide) gels under reducing conditions and
transferred onto PVDF membranes. Membranes were probed overnight
(o/n) at 4C with anti-NR1 (1:1000; Upstate, Lake Placid, NY) or anti-b-actin
(1:250; Sigma, St. Louis, MO) antibodies. Detection was carried out using
ECL reagents (GE Healthcare Europe GmbH, Freiburg, Germany).RECEPTOR BINDING ASSAYFor binding assays on SW1353 and rat chondrocytes, the medium was
removed and cells were washed three times with PBS. In preliminary studies,
chondrocyte membranes and intact cells were tested in parallel. All other as-
says were carried out using intact chondrocytes and were performed in 1 ml
binding buffer (20 mM HEPES, 140 mM NaCl, 2.8 mM KCl, 1 mM CaCl2,
10 mM glucose, pH 7.4), without magnesium. [3H]MK-801 (3 nM) was incu-
bated for 90 min at 25C in the absence (total binding) or presence of test
compounds. In selected experiments, magnesium and zinc cations were
added at concentrations known to maximally inhibit the speciﬁc binding of
[3H]MK-801 to the central NMDA receptor. At the end of the incubation pe-
riod, cells were washed three times with ice-cold binding buffer and hydro-
lyzed in 0.5 M NaOH, and bound radioactivity was quantiﬁed. Speciﬁc
binding was calculated as the difference between the total binding and the
binding in the presence of 50 mM MK-801.
Binding assays to rat brain cortical membranes were carried out using
washed crude synaptic membranes (250e300 mg protein), according to Fos-
ter and Wong21 but in the same buffer as above. The membrane suspension
was incubated for 60 min at 25C with [3H]MK-801 (2.5 nM), in the absence
or presence of 100 mM MK-801 (non-speciﬁc binding). Protein concentration
was determined by the Bradford method, using bovine serum albumin (BSA)
as a standard.SMALL INTERFERING RNA (siRNA)siRNAs expressed from short hairpin RNAs (shRNAs) are a powerful way
to mediate gene speciﬁc RNA interference (RNAi) in mammalian cells. For
our knock-down experiments we used the MISSION product line from Sigma,
which uses a viral vector-based RNAi library against human genes. This li-
brary consists of sequence-veriﬁed shRNA lentiviral plasmid vectors target-
ing human NR1 (more speciﬁcally, a clone set of ﬁve individual constructs
1078 T. Piepoli et al.: Glutamate signaling in chondrocytestargeting different regions of the gene sequence). We obtained the plasmids
directly from Sigma.
To permit accurate interpretation of knock-down results and provide as-
surance of the speciﬁcity of the response observed, an empty pLKO.1-
puro vector was used as a negative control (mock). Cells were transfected
with the ﬁve different shRNA vectors for NR1 knock-down (MISSION
pLKO.1-puro GRIN1 vector) by FuGENE 6 Transfection Reagent (Roche).
Transfected cells were selected by puromycin. NR1 subunit knock-down
was determined by RT-PCR analysis. The different clones obtained were
named with the code pLKO-block letter (e.g., pLKO-A).
Proliferation studies (up to 9 days) were done by colorimetric MTT assay
(Roche).STATISTICAL ANALYSISUnless otherwise indicated, results are presented as mean standard er-
ror (SE). Data were analyzed by one-way analysis of variance (ANOVA)
(gene expression experiments), two-way ANOVA for repeated measures
(proliferation experiments), or unpaired t-test (glutamate release and uptake,
and GLAST-1 expression). A P value of 0.05 or less was considered statis-
tically signiﬁcant.ResultsGLUTAMATE RELEASE AND UPTAKE, AND VESICLE
RECYCLINGEndogenous glutamate was spontaneously released both
from human chondrosarcoma cells and from rat articular
chondrocytes. After 30 min of incubation, SW1353 cells re-
leased 21.3 4.6 nmol glutamate/mg protein (n¼ 8), and
rat articular chondrocytes released 55.7 2.4 nmol0
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Fig. 1. Glutamate uptake. (A) [3H]glutamate accumulation was measured in
20 min of incubation in complete HKR buffer or in HKR buffer without Ca
(rat chondrocytes) independent tests is shown. Bars represent the me
*P< 0.05 vs HKR buffer, by t-test. (B) Effect of calcium on [3H]glutamate u
samples from two independent experiments. Similar results were obtained
cumulation was measured in SW1353 cells (closed bars) and rat chondro
ence of TBOA 100 mM. A representative experiment of three (SW1353) or
the meanSE of triplicate samples or the mean of duplicate samples. *P
GLAST-1 in SW1353 cells. The arrow shows that there was no ampliﬁcati
chondrocytes. Rn: normalized reporter (i.e., the level of ﬂuorescence dete
[human] or 18S [rglutamate/mg protein (n¼ 3). Cell permeabilization with Tri-
ton X-100 allowed estimation of the intracellular concentra-
tion of free glutamate, which was lower in SW1353 cells
than in rat articular chondrocytes (55.3 9.8 and
112.5 21.4 nmol/mg protein, respectively).
In uptake experiments at 37C, the accumulation of
[3H]glutamate was linear with time up to 1 h, whereas no rel-
evant accumulation was seen when cells were incubated at
2C (not shown). After 20 min of incubation at 37C, [3H]glu-
tamate concentrations ranged from 13 to 90 pmol/mg pro-
tein in SW1353 cells and from 100 to 500 pmol/mg protein
in rat articular chondrocytes. The uptake of [3H]glutamate
was Naþ- and Ca2þ-dependent in both cell types
[Fig. 1(A, B), and Supplementary Fig. S1] and was signiﬁ-
cantly inhibited by 100 mM TBOA, a speciﬁc blocker of glu-
tamate transporters [Fig. 1(C)]. In agreement with this
ﬁnding, RT-PCR analysis revealed constitutive expression
of mRNA for the glutamate transporter GLAST-1 in both cul-
tures [Fig. 1(D)].
Vesicle recycling activity was demonstrated in SW1353
cells by using the styryl dye FM1-43. Cells rapidly accumu-
lated the ﬂuorescent dye over a 20-min incubation period;
after removal of FM1-43 from the medium, destaining was
complete within 30 min (Fig. 2).COMPOSITION OF THE NMDA RECEPTOR IN CHONDROCYTESMessenger RNAs for different subunits of the NMDA
receptor, namely NR1, NR2A, NR2C, and NR2D, were10
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SW1353 cells (closed bars) and rat chondrocytes (open bars) after
2þ or Naþ. A representative experiment of three (SW1353) or two
an SE of triplicate samples or the mean of duplicate samples.
ptake in rat chondrocytes. Bars represent the mean of quadruplicate
with SW1353 cells (Supplementary Fig. S1). (C) [3H]glutamate ac-
cytes (open bars) after 20 min of incubation in the absence or pres-
two (rat chondrocytes) independent tests is shown. Bars represent
< 0.05 vs control, by t-test. (D) Representative ampliﬁcation plot of
on in the blank (H2O). A similar plot was obtained using rat articular
cted during PCR, expressed as the ratio of target mRNA to GAPDH
at] mRNA).
SW1353
10
NR1NR2ANR2DPSD95
n
A
Fig. 2. Vesicular recycling. SW1353 cells were incubated in the presence of 10 mM FM1-43 up to 20 min (ﬁrst two panels). FM1-43 was then
removed from the medium, and cells were followed until destaining was complete (last panel). Results from a representative experiment are
shown. Similar results were obtained in three independent experiments.
1079Osteoarthritis and Cartilage Vol. 17, No. 8detected in both cell types. The pattern of expression in
SW1353 cells was similar to that seen in rat articular chon-
drocytes. NR2D was the most abundantly expressed sub-
unit, as determined by the lower number of cycles
required to reach the exponential phase of ampliﬁcation.
Conversely, there was little or no expression of NR2B
[Fig. 3(A)]. Western Blot analysis demonstrated the pres-
ence of NR1 protein [Fig. 3(B)]. In addition, both cell types
were found to express mRNA encoding PSD-95
[Fig. 3(A)], a protein required for proper clustering of gluta-
mate receptors22.1 NR2CNR2B
RBINDING STUDIESCycle number
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Fig. 3. Molecular composition of the NMDA receptor in chondro-
cytes. Results from a representative experiment performed in tripli-
cate are shown. Similar results were obtained in three independent
experiments. (A) Ampliﬁcation plot of different NMDA receptor sub-In preliminary competition experiments, we found that the
binding afﬁnity of MK-801 was similar in chondrocyte mem-
branes and intact cells (IC50s around 1 mM). Thus, to char-
acterize pharmacologically this peripheral NMDA receptor,
we evaluated the speciﬁc binding of [3H]MK-801 to intact
chondrocytes. There was no signiﬁcant difference between
the association rate constants in the absence or presence
of 100 mM glutamate and 30 mM glycine (not shown), both
of which increase [3H]MK-801 binding to brain mem-
branes21,23. Moreover, the binding afﬁnity of [3H]MK-801
was much lower in chondrocytes than in rat brain mem-
branes; mean Kd (dissociation constant) values of 700
and 2.6 nM, respectively, were calculated from two inde-
pendent experiments with similar results.
Competition curves were then generated for the following
inhibitors of [3H]MK-801 binding: MK-801, phencyclidine,
and memantine. All these compounds displayed micromolar
afﬁnity for the NMDA receptor expressed in chondrocytes.
The IC50 values of MK-801 and phencyclidine were, respec-
tively, about 70 and 40 times higher in chondrocytes than in
rat brain membranes. Conversely, the IC50 of memantine
was about ﬁve times lower in chondrocytes (Table I).
The modulatory effects of divalent cations on [3H]MK-801
binding were also investigated. In SW1353 and rat primary
cultures, Mg2þ (100 mM) inhibited [3H]MK-801 binding by
approximately 36 and 61%, respectively, whereas inhibition
by Zn2þ (0.3 mM) did not exceed 50% in either cell type
(Table I).units and PSD-95 in SW1353 cells and rat articular chondrocytes:
the higher the expression of a transcript, the lower the number of
cycles required to reach the exponential phase of ampliﬁcation.
Rn: normalized reporter (i.e., the level of ﬂuorescence detected dur-EFFECT OF GLUTAMATE SIGNALING ON CHONDROCYTE
PROLIFERATIONing PCR, expressed as the ratio of target mRNA to GAPDH [human]
or 18S [rat] mRNA). (B) Western Blot analysis of NR1 and b-actin.
Lane 1: SW1353 (40 mg of total proteins). Lane 2: rat articular chon-
drocytes (40 mg of total proteins). Lane 3: rat brain extract (10 mg of
total proteins). Lane 4: molecular weight markers (kd).To gain insight into the role of glutamate signaling via the
NMDA receptor in chondrocytes, we knocked-down the ex-
pression of NR1 in SW1353 cells, using RNAi. After trans-
fection, we observed that some pLKO clones proliferatedslowly. Thus, clones expressing low levels of NR1 mRNA
(i.e., less than 30% of that found in mock-transfected cells)
were isolated and tested for proliferation. Consistent with
our preliminary observation, SW1353 pLKO clones
Table I
Binding affinities of different molecules to the NMDA receptor and
the effects of divalent cations on [3H]MK-801 binding
SW1353 Rat
chondrocytes
Rat brain
membranes
Binding afﬁnity, IC50, mM
MK-801 1.1 0.4 1.7 0.5 0.023 0.004
Memantine 1.7 0.2 1.3 0.4 6.9 2.0
Phencyclidine 6.8 1.5 9.3 2.4 0.19 0.02
Inhibition of [3H]MK-801 speciﬁc binding, %
Mg2þ (100 mM) 36% 61% 81%
Zn2þ (0.3 mM) 47% 31% 84%
1080 T. Piepoli et al.: Glutamate signaling in chondrocytesproliferated less rapidly than did wild type and mock-trans-
fected cells [P< 0.05; Fig. 4(A)], as determined by MTT
assay.
To conﬁrm the speciﬁcity of this antiproliferative effect,
wild type SW1353 cells were cultured in the absence or
presence of the NMDA receptor antagonist MK-801
(10e100 mM). As shown in Fig. 4(B), sustained exposure
to MK-801 resulted in decreased cell proliferation. This0.00
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Fig. 4. Effect of glutamate signaling on chondrocyte proliferation.
Results (meanSE) from representative experiments performed
in triplicate are shown. Similar results were obtained in two inde-
pendent experiments. (A) NR1 subunit was knocked-down in
SW1353 cells using RNAi, and cell proliferation was tested by
MTT assay. Wild type SW1353 (open circle), mock-transfected
cells (closed square), and two different NR1 knock-down clo-
nesdpLKO-A (star) and pLKO-B (closed triangle)dwere used.
*P< 0.001 vs mock-transfected cells, by two-way repeated mea-
sures ANOVA. (B) Proliferation of SW1353 in the presence of in-
creasing MK-801 concentrations: control (no treatment; closed
circle); 10 mM MK-801 (open square); 50 mM MK-801 (open trian-
gle); 100 mM MK-801 (open circle). *P< 0.001 vs control, by two-
way repeated measures ANOVA.response was concentration-dependent and was not re-
lated to cytotoxicity, given that MK-801 did not inﬂuence
cell viability during the ﬁrst 48 h, as assessed by a cell-
counting system that distinguishes viable from dead cells
(Supplementary Fig. S2). Similar results were obtained in
experiments using rat articular chondrocytes (n¼ 2; not
shown).INVOLVEMENT OF GLUTAMATE SIGNALING IN THE
INFLAMMATORY RESPONSE INDUCED BY IL-1bRecent evidence suggests that increased glutamate
levels are present in the synovial ﬂuid of patients with active
arthropathies, including OA14. We thus tested the effects of
IL-1b, the main cytokine responsible for cartilage degrada-
tion in OA, on glutamate release and uptake. After short-
term (15 min) treatment with 2 ng/ml IL-1b, glutamate
release from SW1353 cells and rat articular chondrocytes
increased signiﬁcantly over control values [by about 90
and 120%, respectively; Fig. 5(A)]. Short-term incubation
with IL-1b did not affect [3H]glutamate uptake (not shown).
However, the uptake of [3H]glutamate decreased by about
50% [P< 0.01; Fig. 5(B)] in SW1353 cells exposed for
48 h to the cytokine, whereas it was not signiﬁcantly af-
fected in rat articular chondrocytes under the same condi-
tions. In agreement with this ﬁnding, IL-1b signiﬁcantly
inhibited the expression of GLAST-1 mRNA in SW1353
cells only [Fig. 5(C)].
We ﬁnally investigated whether agonism/antagonism at
the NMDA receptor could modulate the gene expression
of cytokines and enzymes involved in cartilage degradation.
IL-1b increased the expression of COX-2, IL-1b, IL-6, and
MMP-3 mRNA in both cell types. In agreement with this
ﬁnding, in silico analysis revealed the presence of common
binding sites for transcription factors (e.g., NF-kB and AP-1)
in the promoter regions of these genes (Supplementary
Table S1). Exogenous glutamate and NMDA neither
induced the expression of the genes analyzed nor signiﬁ-
cantly altered the effect of IL-1b (data not shown). Instead,
MK-801 inhibited the response to IL-1b in a concentration-
dependent manner, although signiﬁcant effects were gener-
ally observed only at the highest concentration tested
(100 mM; Fig. 6). No inhibition was seen when IL-8 tran-
script levels were analyzed (not shown).Discussion
We report that chondrocytes express a self-sufﬁcient ma-
chinery for glutamate signaling, including a peripheral
NMDA receptor with unique properties. Depending on
whether signaling is physiological or pathological, this pe-
ripheral NMDA receptor may be involved in chondrocyte
proliferation or in the inﬂammatory process associated
with cartilage destruction. We used the human chondrosar-
coma cell line SW1353 because it is a well-established
chondrocyte model17,18. Parallel experiments with primary
chondrocytes allowed to validate the results obtained.
Yoneda and his group have demonstrated that rat costal
chondrocytes release endogenous glutamate and accumu-
late [3H]glutamate9,11. In extending these ﬁndings to
SW1353 cells and rat articular chondrocytes, we noticed
a peculiarity that is worth mentioning. That is, in addition
to being sodium-dependent as it is in glial cells and neu-
rons24, [3H]glutamate uptake into chondrocytes was cal-
cium-dependent. To our knowledge, no such effect of
calcium has been previously reported in the literature.
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Fig. 5. Effect of IL-1b on glutamate release and uptake. Results
(meanSE) from representative experiments performed in tripli-
cate are shown. Similar results were obtained in at least three inde-
pendent experiments. (A) Glutamate release in the absence
(control; open bars) or presence of 2 ng/ml IL-1b (closed bars), after
15 min of incubation. *P< 0.05 vs respective control, by t-test. (B)
[3H]glutamate uptake in the absence (control; open bars) or pres-
ence of 10 ng/ml IL-1b (closed bars), after 20 min of incubation.
*P< 0.001 vs control, by t-test. (C) The gene expression of the glu-
tamate/aspartate transporter GLAST-1 was analyzed after incuba-
tion for 6 h with 2 ng/ml IL-1b. Control (open bars); IL-1b (closed
bars). *P< 0.01 vs control, by t-test.
1081Osteoarthritis and Cartilage Vol. 17, No. 8Although it was not our main goal to study glutamate
transport in chondrocytes, we demonstrated the expression
of mRNA for the glial transporter GLAST-1. Glutamate re-
lease and uptake were accompanied by vesicle recycling
activity, as shown by experiments with the ﬂuorescent dye
FM1-43, which becomes incorporated into the vesicular
membrane during endocytosis. This ﬁnding is consistent
with previous studies showing that osteoblasts regulate ex-
tracellular levels of glutamate by virtue of a self-sufﬁcient
machinery20,25, whereas neurons rely on astrocytes for
the bulk of glutamate uptake from the synaptic cleft24.Several possibilities of glutamate origin are conceivable in
bone, including glutamatergic ﬁbers and blood vessels.
Conversely, chondrocytes themselves might be the main
source of glutamate within the cartilage matrix because nei-
ther innervation nor vascularization is present within normal
articular cartilage10.
Cartilage cells have been shown to express various com-
ponents of the glutamate system9e12. In the present study
we found constitutive expression of mRNA for different sub-
units of the NMDA receptor, with NR2D being the most
abundantly expressed. Little or no expression of NR2B
was detected in SW1353 cells and rat articular chondro-
cytes, in contrast with what is generally observed in the
CNS26 but in agreement with the most recent ﬁndings in
chondrocytes from healthy subjects27. Like human primary
chondrocytes, both SW1353 cells and rat articular chondro-
cytes also expressed mRNA encoding PSD-95. PSD-95
promotes anchoring of the NMDA receptor to the postsyn-
aptic density and connects it to downstream signaling mol-
ecules22,27. Therefore, its expression points to a functional
receptor anchored to the cellular membrane.
Binding studies revealed large differencesdmainly with
regard to the bindingafﬁnity ofMK-801dbetween the receptor
expressed in chondrocytes and that expressed in brain. This
result was not unexpected, as ligand afﬁnities at recombinant
NMDA receptors depend on their subunit composition. In
support of our ﬁnding that NR2D is abundantly expressed
in chondrocytes, MK-801 shows the following afﬁnity ranking:
NR1eNR2A¼NR1eNR2B[NR1eNR2C¼NR1eNR2D28.
In the present study, the afﬁnity of [3H]MK-801 binding in
rat brain membranes was in line with published data21.
Thus, our results argue in favor of a peripheral receptor with
distinct pharmacological characteristics.
Another peculiarity of the chondrocyte receptor was the
low sensitivity to the divalent cations Mg2þand Zn2þ. Inter-
estingly, the extent of Mg2þ blockade depends on the
structural arrangement of the NMDA receptor-channel com-
plex29, and channels containing NR2D are less sensitive to
Mg2þ than those containing NR2B30.
To study the physiological function of NMDA receptors in
chondrocytes we chose to knock-down the expression of
NR1, the subunit required to form functional channels29.
Knock-down clones grew slower than wild type cells, point-
ing to a direct involvement of glutamate signaling in chon-
drocyte proliferation. Parallel experiments, in which
chondrocytes were cultured in the presence of the NMDA
receptor antagonist MK-801, substantiated this hypothesis.
Glutamate has been shown to suppress the proliferation of
mesenchymal stem cells31, which have the potential to dif-
ferentiate into chondrocytes, but no study had previously
tested the effect of NMDA receptor blockade (or NR1
knock-down) on chondrocyte proliferation. In synoviocytes,
the antiproliferative activity of glutamate receptor antago-
nists is concentration-dependent and similar to that of
antirheumatic drugs32. In chondrocytes, the response to
MK-801 was concentration-dependent as well, and the
high concentrations required to produce a signiﬁcant effect
are in keeping with the low afﬁnity observed in binding
studies.
Beyond the physiological role of glutamate in joints, grow-
ing evidence indicates that glutamate-mediated events may
contribute to the pathogenesis of human arthritic conditions.
Increased levels of glutamate are seen in the knee joint of
rats with early OA33,34 and, most importantly, in the synovial
ﬂuid of patients with active arthropathies13. Signiﬁcant asso-
ciations between excitatory amino acids and inﬂammatory
mediators have been demonstrated in the synovium of
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Fig. 6. IL-1b-induced expression of inﬂammatory mediators and matrix-degradative enzymes: effect of MK-801. Transcript levels of selected
genes were analyzed after incubation of SW1353 cells (closed bars) and rat chondrocytes (open bars) for 6 h. Cells were treated with IL-1b in
the absence or presence of increasing concentrations of MK-801. Results (meanSE) from a representative experiment performed in trip-
licate are shown. Similar results were obtained in three independent experiments. *P< 0.05 vs IL-1b, by one-way ANOVA.
1082 T. Piepoli et al.: Glutamate signaling in chondrocytesthese patients14. Based on this evidence we examined
whether IL-1b, the main cytokine responsible for cartilage
destruction in OA16, could affect glutamate signaling in
chondrocytes. IL-1b increased glutamate release in both
cell types while inhibiting glutamate uptake and GLAST-1
expression in SW1353 cells only. Data from the literature
suggest that the effects of inﬂammatory mediators on gluta-
mate uptake/EAAT expression may depend on the cell type
and species studied. For instance, inﬂammatory cytokines
inhibit glutamate uptake in human but not murine astrocytes
in culture, whereas lipopolysaccharide increases GLT-1
levels and glutamate uptake in rat microglial cells35e37.
Other authors have found increased GLAST expression in
cartilage specimens from rabbits 30 weeks after anterior
cruciate ligament transection (ACLT)38. We agree with
these authors that EAATs may be involved in the pathogen-
esis of OA, but their role is far from being understood.
In OA, the balance between cartilage degradation and
synthesis is shifted toward catabolism. IL-1b plays a major
role in activating this catabolic cascade, which involves
many pro-inﬂammatory mediators and enzymes16,18,39. In
our experiments, IL-1b increased the gene expression of
key cytokines and enzymes involved in cartilage degrada-
tion. MK-801 inhibited this response in a concentration-de-
pendent fashion, suggesting the potential involvement of
the NMDA receptor in joint inﬂammation. Again, signiﬁcant
effects were seen only at high concentrations, possibly be-
cause of the low ligand-receptor afﬁnity. An alternative ex-
planation, also suggested by Hinoi et al. for cultured
osteoblasts8, is that NMDA receptors were constantly stim-
ulated by glutamate in the medium. Tonic stimulation may
also have masked an effect of NMDA receptor agonists,whose contribution (if any) to IL-1b-induced gene expres-
sion could not be determined. Indeed, chondrocytes started
being non-viable after a few hours of incubation in a medium
not containing glutamine or glutamate, making it unfeasible
to assess gene expression under these control conditions.
In conclusion, this is the ﬁrst evidence that glutamate may
function as an autocrine factor in chondrocytes under both
physiological and pathological conditions. Our ﬁndings
complement and extend the results of a recent study by
Salter and his group, who demonstrated altered composi-
tion and activity of NMDA receptors in osteoarthritic chon-
drocytes27. In particular, new information is provided in
support of the following hypothesis by these authors:
‘‘NMDA receptor signaling is likely to have a variety of im-
portant functions in cartilage and depending on whether sig-
naling is physiological or pathological, maintains healthy
cartilage or contributes to the pathological changes in
OA’’27. Therefore, the chondrocyte NMDA receptor could
be a target for new drugs with therapeutic potential in OA.Conﬂict of interest
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